CAPhO 2026 Therapy Choice in ER-Low, HER2-Low, and Triple Negative Breast Cancer

Concurrent session

Advances in breast cancer research are reshaping diagnostic frameworks and influencing treatment strategies. This presentation explores emerging classifications in breast cancer, focusing on ER-low, HER2-low, and triple-negative breast cancer and their growing clinical relevance. It provides clarity on current approaches to receptor status assessment, interpretation of pathology reports, and the practical implications of these distinctions for therapy choice. The session offers insights to support evidence-based decision-making and facilitate the integration of evolving concepts into everyday clinical practice.